KLK3 and metastatic neoplasm: There were higher median PSA (60.25 vs. 10.35 ng/mL) and a higher number of patients who did not have local therapy before receiving treatment for metastatic disease (78 vs. 44%), among the patients in the >14-day group compared to the 1–6-day group.